• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Chikashi Yoshida, Takuya Komeno, +16 authors Hiroshi Kojima
  • Medicine
  • International journal of hematology
  • 2011 (First Publication: 22 April 2011)
  • The correlation between imatinib (IM) trough plasma concentration (Cmin) and clinical response was assessed in patients with chronic-phase chronic myeloid leukemia. The Cmin correlated with neitherExpand
  • Hiroshi Kojima, Yuichi Hasegawa, +12 authors Toshiro Nagasawa
  • Medicine
  • Leukemia research
  • 2004 (First Publication: 1 December 2004)
  • Clinicopathological features of 36 patients, male: 58.3%; median: 68 years, with "peripheral T-cell lymphoma, unspecified" diagnosed by the WHO criteria were reviewed. Majority (69.4%) had stage IVExpand
  • Tatsuo Ichinohe, Yoshiaki Kuroda, +16 authors Shotaro Hagiwara
  • Medicine
  • Experimental Hematology & Oncology
  • 2015 (First Publication: 18 April 2016)
  • AbstractBackgroundThe immunomodulatory agent pomalidomide in combination with low-dose dexamethasone has demonstrated efficacy and safety for the treatment of relapsed and refractory multiple myelomaExpand
  • Daisuke Kudo, Takuya Komeno, +18 authors Hiroshi Kojima
  • Medicine
  • 2018 (First Publication: 29 November 2018)
  • Introduction: Although a previous study with small numbers of patients (Pts) reported comparable efficacy and less toxicity of once-weekly CBD as an induction compared to twice-weekly CBD for newlyExpand
  • Keisuke Tanaka, Shigeo Toyota, +23 authors Hiroshi Kojima
  • Medicine
  • Acta Haematologica
  • 2019
  • We assessed the efficacy and safety of weekly cyclophosphamide-bortezomib-dexamethasone (CBD) induction prior to autologous stem cell transplantation (ASCT) in newly diagnosed Japanese patients withExpand
  • Yukiko Cho, Mitsuo Hori, +13 authors Hiroshi Kojima
  • Medicine
  • Acta Haematologica
  • 2015 (First Publication: 29 June 2015)
  • Aims: To explore the biomarker for predicting the occurrence of adverse events in myeloma patients treated by intravenous bortezomib, we measured proteasome activity in peripheral blood mononuclearExpand
  • Ikuyo Tsutsumi, Susumu Kunisawa, +5 authors Yuichi Imanaka
  • Medicine
  • International Journal of Clinical Oncology
  • 2019 (First Publication: 12 July 2019)
  • The prevention of invasive fungal infections is important in patients with acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) receiving cytoreductive chemotherapy. However, the role of oralExpand